Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Si ^a   Shi, Danyang ^a   Wang, Hai Chao ^b   Yu, Yun Zhou ^a   Xu, Qing ^b   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b BEIJING JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DNA VACCINE; IMMUNOGLOBULIN G;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BRAIN; C57BL MOUSE; CELL POLARITY; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MUTANT MOUSE STRAIN; PATHOLOGY; PATHOPHYSIOLOGY; SPATIAL MEMORY; TH2 CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BRAIN; CELL POLARITY; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INFLAMMATION; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PLAQUE, AMYLOID; SPATIAL MEMORY; TH2 CELLS; VACCINES, DNA;

EID: 84923086732     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07771     Document Type: Article

References (45)

1. Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-b immunotherapy? Nat Rev Neurosci 6, 108-119 (2010).
2. Town, T. Inflammation, Immunity, and Alzheimer's Disease. CNS Neurol Disord Drug Targets 9, 129-131 (2010).
3. Wisniewski, T. & Boutajangout, A. Vaccination as a therapeutic approach for Alzheimer's disease. Mt Sinai J Med 77, 17-31 (2010).
4. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
5. Morgan, D. Immunotherapy for Alzheimer's Disease. J Gen Intern Med 269, 54-63 (2011).
6. Muhs, A. et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104, 9810-9815 (2007).
7. Ghochikyan, A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's Disease immunotherapy. CNS Neurol Disord Drug Targets 8, 128-146 (2009).
8. Olkhanud, P. B. et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid b-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 30, 1650-1658 (2012).
9. Savonenko, A. V. et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacol 37, 261-277 (2011).
10. Morgan, D. et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
11. Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's Disease. Neuron 38, 547-554 (2003).
12. Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919 (2000).
13. Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54 (2003).
14. Cribbs, D. H. et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 15, 505-514 (2003).
15. Morgan, D. & Gitter, B. D. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol Aging 25, 605-608 (2004).
16. Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. Clinical trials in Alzheimer's disease:immunotherapy approaches. J Neurochem 120, 186-193 (2012).
17. Moretto, N. et al. Conformation-sensitive Antibodies against Alzheimer Amyloid-b by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide. J Biol Chem 282, 11436-11445 (2007).
18. Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-lockbing peptides. Immunity 1, 751-761 (1994).
19. Alexander, J. et al. The Optimization of Helper T Lymphocyte (HTL) Function in Vaccine Development. Immunol Res 18, 79-92 (1998).
20. Alexander, J. et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 164, 1625-1633 (2000).
21. Yu, Y. Z. et al. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant. Clin Immunol 149, 11-24 (2013).
22. Yu, Y. Z. et al. Strikingly Reduced Amyloid burden and improved behavioral performance inAlzheimer's Disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Ab1-15 fused to toxin-derived carrier proteins. J Alzheimers Dis 41, 243-260 (2014).
23. Schenk, D. Amyloid-b immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3, 824-828 (2002).
24. Gilman, S. et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562 (2005).
25. Lambracht-Washington, D. et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Ab42 DNA vaccine for Alzheimer disease. J Neuroimmunol 254, 63-68 (2013).
26. Davtyan, H. et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 17, 261-271 (2010).
27. Jin, J. et al. An immunotherapeutic treatment against flea allergy dermatitis in cats by co-immunization ofDNA and protein vaccines. Vaccine 28, 1997-2004 (2010).
28. Li, J. Y. et al. Regulatory dendritic cells by DNA and plays a critical role in the induction of Caveolin-1-mediated negative signaling protein coimmunization. J Immunol 189, 2852-2859 (2012).
29. Li, J. et al. Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary. J Gene Med 9, 1095-1103 (2007).
30. Li, J. et al. Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells. J Gene Med 10, 810-820 (2008).
31. Monsonego, A., Nemirovsky, A. & Harpaz, I. CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology 139, 438-446 (2013).
32. Pimplikar, S. W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. INT J Biochem Cell Biol 41, 1261-1268 (2009).
33. Menendez-Gonzalez, M., Perez-Pinera, P., Martinez-Rivera, M., Lopez Muniz, A. & Vega, J. A. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des 17, 508-520 (2011).
34. Cribbs, D. H. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets 9, 207-216 (2010).
35. Wisniewski, T. & Boutajangout, A. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct 214, 201-218 (2010).
36. Pasquali, J. L., Soulas-Sprauel, P., Korganow, A. S. & Martin, T. Auto-reactive B cells in transgenic mice. J Autoimmun 29, 250-256 (2007).
37. Bayer, A. J. et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94-101 (2005).
38. Patton, R. L. et al. Amyloid-b peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. AM J Pathol 169, 1048-1063 (2006).
39. Chen, G.etal. Activeb-amyloid immunization restores spatial learninginPDAPP mice displaying very low levels of b-amyloid. J Neurosci 27 (2007)
40. Walter, J. et al. A new role for interferon gamma in neural stem/precursor cell dysregulation. Mol Neurodegener 6, 18-29 (2011).
41. Mastrangelo, M. A., Sudol, K. L., Narrow, W. C. & Bowers, W. J. Interferon-c differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. AM J Pathol 175, 2076-2088 (2009).
42. Browne, T. C. et al. IFN-c production by amyloid b-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's Disease. J Immunol 190, 2241-2251 (2013).
43. Wang, S. et al. A coimmunization vaccine of Ab42 ameliorates cognitive deficits without brain inflammationinanAlzheimer's disease model. Alzheimers Res Ther 6, 26 (2014).
44. Yu, Y. Z., Li, N., Wang, S., Yu, W. Y. & Sun, Z. W. Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting. Immunopharm Immunot 31, 397-404 (2009).
45. Zhang, J. et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and b-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14, 365-379 (2003).